Search Articles

View query in Help articles search
e.g. John Smith or 0000-0001-6479-5330

Search Results (1 to 3 of 3 Results)

Download search results: CSV END BibTex RIS

Potential Effects of an Exoskeleton-Assisted Overground Walking Program for Individuals With Spinal Cord Injury Who Uses a Wheelchair on Imaging and Serum Markers of Bone Strength: Pre-Post Study

Potential Effects of an Exoskeleton-Assisted Overground Walking Program for Individuals With Spinal Cord Injury Who Uses a Wheelchair on Imaging and Serum Markers of Bone Strength: Pre-Post Study

Summary of dual-energy x-ray absorptiometry outcome measures (N=10). a Standardized effect sizes interpreted as N=negligible ( b∆=relative variation between medians (positive indicates an increase in value from pre- to postmeasurement). c Italics format indicates variables meeting the following 3 criteria: statistically significant difference, effect size ≥0.5, and relative median difference ≥5%. d Statistically significant difference (P≤.10) for Wilcoxon signed rank tests.

Alec Bass, Suzanne N Morin, Michael Guidea, Jacqueline T A T Lam, Antony D Karelis, Mylène Aubertin-Leheudre, Dany H Gagnon, Montreal Exoskeleton Walking Program (MEWP) Group

JMIR Rehabil Assist Technol 2024;11:e53084

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 3

Effects of an Overground Walking Program With a Robotic Exoskeleton on Long-Term Manual Wheelchair Users With a Chronic Spinal Cord Injury: Protocol for a Self-Controlled Interventional Study

Effects of an Overground Walking Program With a Robotic Exoskeleton on Long-Term Manual Wheelchair Users With a Chronic Spinal Cord Injury: Protocol for a Self-Controlled Interventional Study

Fasting blood samples (ie, >8-hour fast) are used to quantify bone turnover biomarkers (ie, serum procollagen type 1 N-terminal peptide, osteocalcin, C-terminal cross-linking telopeptide, and 25-hydroxyvitamin D), glycemic biomarkers (ie, fasting glucose, insulin, and glycosylated hemoglobin), insulin resistance biomarkers (ie, homeostatic model assessment), lipid biomarkers (ie, total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and apolipoprotein B), and inflammatory biomarkers

Alec Bass, Mylène Aubertin-Leheudre, Claude Vincent, Antony D Karelis, Suzanne N Morin, Michelle McKerral, Cyril Duclos, Dany H Gagnon

JMIR Res Protoc 2020;9(9):e19251

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 4